CVS Stock Analysis — CVS Health
Sector: Healthcare
AI Verdict
CVS trades at 13.2x forward earnings with nearly double expected EPS, making it cheap for the growth on offer if their vertical integration moat holds up.
Competitive Moat
CVS Health combines a national pharmacy chain, a major health insurer (Aetna), and a pharmacy benefits manager, creating a vertically integrated healthcare platform that locks in customers across the care continuum. This integration gives CVS pricing power and data advantages that are hard for standalone competitors to match.
Summary
CVS's forward P/E of 13.2x with nearly doubled earnings expected (+92.8% EPS growth) makes it a standout in healthcare value.
Where It Stands
CVS is up 46.02% over the past year, sports an extremely oversold RSI of 17.6, and trades at 13.2x next year's earnings versus a sector median of 22x.
Key Metrics
- RSI: 17.6 — Oversold
- Trailing P/E: 25.4x
- Forward P/E: 13.2x
- PEG Ratio: 0.27
- Earnings Growth: +0.9%
- Revenue Growth: +0.1%
- Market Cap: $122.4B
- Dividend Yield: 0.03%
- 1-Year Return: 46.02%
- 52-Week High: $110.68
- 52-Week Low: $62.55
Analyst Consensus
28 Buy · 5 Hold · 0 Sell (33 analysts)
Bull Case
You're paying just 13.2x next year's earnings for a company expected to grow EPS by 92.8%, which is cheap for the growth on offer if their integrated model keeps delivering.
Bear Case
If CVS's forward P/E rerates even halfway back to the sector median of 22x, the current price could see a sharp correction, especially with an RSI of 17.6 signaling exhaustion after a 46.02% run.
Catalyst to Watch
Watch for quarterly earnings updates — if forward EPS guidance slips below the 92.8% growth consensus, the low P/E won't look like a bargain.